Precision BioSciences (DTIL)
(Real Time Quote from BATS)
$4.66 USD
-0.15 (-3.12%)
Updated Aug 7, 2025 11:34 AM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DTIL 4.66 -0.15(-3.12%)
Will DTIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DTIL
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Qiagen (QGEN) Matches Q2 Earnings Estimates
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Other News for DTIL
Precision BioSciences GAAP EPS of -$2.13 misses by $0.56
Precision BioSciences Q2 2025 Earnings: EPS of ($2. ...
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business ...
Precision BioSciences Q2 2025 Earnings Preview
Precision BioSciences reports safety, efficacy data for ELIMINATE-B trial cohort